Diabetic Nephropathy
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Adiponectin rs2241766T/G and rs17300593G/A rather than rs1501299G/T and rs266729C/G polymorphisms were associated with the risk of DN in T2DM, especially in the Caucasian population.
|
24825737 |
2015 |
Diabetic Nephropathy
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The present study aims to evaluate the association of the ACDC genetic variation in T1D and diabetic nephropathy (DN).
|
17189871 |
2007 |
Diabetic Nephropathy
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
We investigated the association of 18 ADIPOQ polymorphisms with DN in a prospective Taiwanese cohort of type 2 diabetes (T2D) and explored whether gender plays a role in this genetic association.
|
24894086 |
2014 |
Diabetic Nephropathy
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The present study provides evidence that MCF2L2, ADIPOQ and SOX2 genetic polymorphisms have effects on the resistance of DN in female T1D patients, and suggests that the linkage with DN in chromosome 3q may be explained by the cumulated genetic effects.
|
20667095 |
2010 |
Diabetic Nephropathy
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
In the present study, we identified the binding sites for transcriptional factors in the adiponectin promoter region and also evaluated the association between adiponectin promoter polymorphisms and diabetic nephropathy (DN) in T1D patients.
|
18599322 |
2009 |
Diabetic Nephropathy
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The minor allele of rs3865188 was associated with lower adiponectin levels (P = 0.006). rs11646213 [odds ratio (OR) 1.47; 95% confidence interval (CI) 1.18-1.85; P = 0.0009] and rs3865188 (OR 0.71; 95% CI 0.57-0.90; P = 0.004) were associated with baseline prevalence of established/advanced DN.
|
28499019 |
2017 |
Diabetic Nephropathy
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The present study aims to examine the association of tumor necrosis factor-α (TNF-α) g.-308 G > A and adiponectin (ADIPOQ) g. + 45 T > G gene polymorphisms in type 2 diabetes (T2D) and its microvascular complications diabetic retinopathy (DR) and diabetic nephropathy (DN).
|
24655058 |
2014 |
Diabetic Nephropathy
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Overall, there was an association between ADIPOQ -11391A allele with increased DN risk (OR = 1.186, 95% CI: 1.051-1.338, p = 0.006).
|
24344808 |
2014 |
Diabetic Nephropathy
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
A comprehensive association analysis of 24 single-nucleotide polymorphisms (SNPs) in the adiponectin gene was performed for type 2 diabetes and diabetic nephropathy in African Americans.
|
19056609 |
2009 |
Diabetic Nephropathy
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
These complimentary approaches have demonstrated that polymorphisms in the carnosinase 1 gene on chromosome 18q, the adiponectin gene on 3q, and the engulfment and cell motility gene on 7p are likely associated with susceptibility to diabetic nephropathy.
|
17942768 |
2007 |
Diabetic Nephropathy
|
0.400 |
Biomarker
|
disease |
CTD_human |
These complimentary approaches have demonstrated that polymorphisms in the carnosinase 1 gene on chromosome 18q, the adiponectin gene on 3q, and the engulfment and cell motility gene on 7p are likely associated with susceptibility to diabetic nephropathy.
|
17942768 |
2007 |
Diabetic Nephropathy
|
0.400 |
Biomarker
|
disease |
BEFREE |
The role of adiponectin in the development of diabetic nephropathy has not been elucidated, and the aim of the present study was to investigate the hypothesis that deletion of the gene for adiponectin would accelerate diabetic nephropathy in the Akita mouse.
|
25957229 |
2015 |
Diabetic Nephropathy
|
0.400 |
Biomarker
|
disease |
BEFREE |
The overall significance for this variant (nominal P = 0.011) suggests that ADIPOQ might be involved in the development of diabetic nephropathy.
|
17065357 |
2006 |
Diabetic Nephropathy
|
0.400 |
Biomarker
|
disease |
BEFREE |
We performed a case-control study to examine whether the SNP276 of the adiponectin gene was also related to early diabetic nephropathy.
|
15334388 |
2004 |
Diabetic Nephropathy
|
0.400 |
Biomarker
|
disease |
BEFREE |
The purpose of this study was to investigate the therapeutic effects and the underlying mechanisms of adiponectin in early DN.
|
24816832 |
2014 |
Diabetic Nephropathy
|
0.400 |
Biomarker
|
disease |
BEFREE |
Our results indicate that 11 genetic variants within or near VEGFA, CCR5, CCL2, IL-1, MMP9, EPO, IL-8, ADIPOQ and IL-10 showed significant positive association with diabetic nephropathy.
|
25280384 |
2014 |
Diabetic Nephropathy
|
0.400 |
Biomarker
|
disease |
BEFREE |
Adiponectin exhibits its biological effects through adiponectin receptors (AdipoR1 and AdipoR2), which are distributed in the kidneys, and activation of those receptors could prevent or ameliorate diabetic nephropathy.
|
30135333 |
2019 |
Diabetic Nephropathy
|
0.400 |
Biomarker
|
disease |
BEFREE |
Urinary adiponectin as a new diagnostic index for chronic kidney disease due to diabetic nephropathy.
|
31245009 |
2019 |
Diabetic Nephropathy
|
0.400 |
Biomarker
|
disease |
BEFREE |
We propose AdipoRon, an orally active synthetic adiponectin receptor agonist as a promising drug for restoration of DKD without inducing systemic adverse effects.
|
30974901 |
2019 |
Diabetic Nephropathy
|
0.400 |
Biomarker
|
disease |
BEFREE |
Adiponectin improves diabetic nephropathy by inhibiting necrotic apoptosis.
|
31572480 |
2019 |
Diabetic Nephropathy
|
0.400 |
Biomarker
|
disease |
BEFREE |
Serum adiponectin predicts all-cause mortality and end stage renal disease in patients with type I diabetes and diabetic nephropathy.
|
18496510 |
2008 |
Diabetic Nephropathy
|
0.400 |
Biomarker
|
disease |
BEFREE |
Adiponectin (ADP) may hold promise as a biomarker for diabetic nephropathy (DN).
|
30557306 |
2018 |
Diabetic Nephropathy
|
0.400 |
Biomarker
|
disease |
BEFREE |
The Adiponectin Receptor Agonist AdipoRon Ameliorates Diabetic Nephropathy in a Model of Type 2 Diabetes.
|
29330340 |
2018 |
Diabetic Nephropathy
|
0.400 |
Biomarker
|
disease |
BEFREE |
Adiponectin protects against the development of albuminuria in rodent experiments and patients with diabetic kidney disease.
|
29894207 |
2019 |
Diabetic Nephropathy
|
0.400 |
Biomarker
|
disease |
BEFREE |
Adiponectin receptor agonist AdipoRon decreased ceramide, and lipotoxicity, and ameliorated diabetic nephropathy.
|
29462574 |
2018 |